Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma Equity Group ASOCSE:PEG -4.00% 3-1 Month Momentum % is 30.46% as of Sep. 09, 2026. The stock has 3 warning signs investors should review. Among 1,386 Biotechnology companies, Pharma Equity Group AS ranks better than 85.64% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-09), Pharma Equity Group AS's 3-1 Month Momentum % is 30.46%.
The industry rank for Pharma Equity Group AS's 3-1 Month Momentum % or its related term are showing as below:
OCSE:PEG's 3-1 Month Momentum % is ranked better than 85.64% of 1386
companies
in the Biotechnology industry
Industry Median: 1.085
vs OCSE:PEG: 30.46
Pharma Equity Group AS (OCSE:PEG) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Pharma Equity Group AS 3-1 Month Momentum % Related Terms
OCSE:PEG vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Pharma Equity Group AS's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Equity Group AS 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Pharma Equity Group AS's 3-1 Month Momentum % falls into.
Pharma Equity Group AS (OCSE:PEG) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Equity Group AS (OCSE:PEG) has a 3-1 Month Momentum % of 30.46% as of Sep. 09, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Pharma Equity Group AS and its competitors. According to the industry distribution chart, Pharma Equity Group AS ranks #199 out of 1386 companies in the Biotechnology industry, placing it in the top 14.4%.
Is Pharma Equity Group AS's 3-1 Month Momentum % too high?
Pharma Equity Group AS's current 3-1 Month Momentum % is 30.46%. The Biotechnology industry median 3-1 Month Momentum % is 1.09. Pharma Equity Group AS's value of 30.46% is 2707.4% above this industry median. Based on the distribution chart, Pharma Equity Group AS ranks #199 out of 1386 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Pharma Equity Group AS's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Equity Group AS ranks #199 out of 1386 companies for 3-1 Month Momentum %. This places Pharma Equity Group AS in the top 14% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 1.09. Pharma Equity Group AS's value of 30.46% is 2707.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 1.09, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Equity Group AS's current 3-1 Month Momentum % of 30.46% is 2707.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Pharma Equity Group AS and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 1.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Equity Group AS's current 3-1 Month Momentum % is 30.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current 3-1 Month Momentum % of 30.46%. The current 3-1 Month Momentum % is 30.46% and 2707.4% above the Biotechnology industry median of 1.09. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current 3-1 Month Momentum % is 30.46% as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:PEG has been successfully added to your 
